The Philippines Food and Drug Administration is set to shorten the timeline for generic review and approval from 120 days to just 45 days, as part of efforts to register new generics and bring down prices.

Japan-UK firm is looking to build on a combination of internal and external assets to pursue a more independent business development path in Japan and beyond, in parallel with ongoing discovery and development collaborations.

Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.

Market expansion services provider has its headquarters in Switzerland but a long history and most of its business in Southeast Asia, where the global head of its Business Unit Healthcare tells Scrip it continues to build a broad range of services based around knowledge and penetration of local markets.